Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.
Pituitary apoplexy is a rare and life-threatening clinical condition caused by hemorrhage and/or infarction of the pituitary gland or adenoma. Although pituitary apoplexy is usually spontaneous, it has been associated with numerous precipitating factors, such as bromocriptine use. However, reports of pituitary apoplexy during cabergoline therapy are scarce. We report three patients with cystic macroprolactinomas who developed pituitary apoplexy during cabergoline treatment.
Balarini Lima
Giovanna Aparecida
GA
Division of Endocrinology, Clementino Fraga Filho University Hospital/Federal University of Rio de Janeiro, Rua Professor Rodolpho Paulo Rocco, no. 255, Cidade Universitária - Ilha do Fundão, Rio de Janeiro, RJ, Brazil.
Machado
Evelyn de Oliveira
Ede O
Dos Santos Silva
Cintia Marques
CM
Filho
Paulo Niemeyer
PN
Gadelha
Mônica Roberto
MR
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000009:adverse effects*; D004873:Ergolines / Q000009:adverse effects*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010899:Pituitary Apoplexy / Q000139:chemically induced* / Q000473:pathology; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015175:Prolactinoma / Q000188:drug therapy* / Q000473:pathology; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline